Highlights
The Phase I CHILD trial confirmed the safety and feasibility of intramyocardial neonatal cardiac progenitor cell (nCPC) injections during the stage 2 palliative operation for Hypoplastic Left Heart Syndrome (HLHS).
The primary efficacy endpoint—improvement in right ventricular (RV) size or function at 1-year follow-up—was not achieved in the randomized cohort.
